Cargando…

Real-world data of HER2-low metastatic breast cancer: A population based cohort study

BACKGROUND: With the introduction of investigational human epidermal growth factor receptor 2 (HER2) targeting treatments, thorough understanding of breast cancer with different HER2 expression levels is critical. The aim of this study was to compare clinicopathologic characteristics and survival of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holthuis, Emily I., Vondeling, Gerard T., Kuiper, Josephina G., Dezentjé, Vincent, Rosenlund, Mats, Overbeek, Jetty A., van Deurzen, Carolien H.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663525/ https://www.ncbi.nlm.nih.gov/pubmed/36375389 http://dx.doi.org/10.1016/j.breast.2022.11.003

Ejemplares similares

Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
por: Dunton, Kyle, et al.
Publicado: (2022)

Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material
por: Berghuis, A. M. Sofie, et al.
Publicado: (2019)

Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study
por: Mansfield, Carol, et al.
Publicado: (2022)

Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control
por: Karlsson, Linda, et al.
Publicado: (2017)

Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries
por: Oppelt, Katja A., et al.
Publicado: (2021)

Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetes
por: Overbeek, Jetty A., et al.
Publicado: (2018)

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
por: Zhang, Qiongwen, et al.
Publicado: (2023)

Carcinoma in situ to invasive breast cancer
por: van Deurzen, Carolien H.M., et al.
Publicado: (2015)

Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases
por: DeBusk, Kendra, et al.
Publicado: (2022)

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
por: van den Ende, Nadine S., et al.
Publicado: (2022)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2− Metastatic Breast Cancer Treated with Abemaciclib
por: Smyth, Emily Nash, et al.
Publicado: (2022)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
por: Gui, Xinyu, et al.
Publicado: (2020)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population
por: Agrawal, Chaturbhuj, et al.
Publicado: (2021)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan
por: Nozawa, K., et al.
Publicado: (2023)

HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study
por: Shao, Yingbo, et al.
Publicado: (2022)

Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study
por: Zhao, Wei, et al.
Publicado: (2020)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Sun, Ying, et al.
Publicado: (2021)

Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
por: Isaksson, Jenny, et al.
Publicado: (2021)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
por: Shao, Yingbo, et al.
Publicado: (2022)

Clinical effectiveness of liraglutide vs basal insulin in a real‐world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes
por: Overbeek, Jetty A., et al.
Publicado: (2018)

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer
por: Steenbruggen, Tessa G., et al.
Publicado: (2023)

Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world
por: Di Cosimo, Serena, et al.
Publicado: (2022)

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
por: Lux, Michael P., et al.
Publicado: (2018)

Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States
por: Zanotti, Giovanni, et al.
Publicado: (2017)

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
por: Vici, Patrizia, et al.
Publicado: (2017)

Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis
por: Statler, Abby B., et al.
Publicado: (2019)

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2021)

Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database
por: Annonay, Mylène, et al.
Publicado: (2021)

Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study
por: Hua, Yijia, et al.
Publicado: (2022)

Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study
por: Li, Chao, et al.
Publicado: (2021)

Efficacy and safety of pyrotinib‐containing regimen in the patients with HER2‐positive metastatic breast cancer: A multicenter real‐world study
por: Yin, Sha, et al.
Publicado: (2022)

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
por: Kaufman, Peter A., et al.
Publicado: (2023)

RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study
por: Wang, Ping, et al.
Publicado: (2023)

Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary
por: Babcock, Aram, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qhlon8b76673rvon3pld82fdda